Cargando…

A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors

The objective of this study was to determine the prognostic value of lymph node (LN) involvement and the LN ratio (LNR) and their effect on recurrence rates and survival in patients with pancreatic neuroendocrine tumors (PNETs) undergoing surgery. This single-center retrospective study reviewed the...

Descripción completa

Detalles Bibliográficos
Autores principales: Osher, Esther, Shalabna, Eiman, Klausner, Joseph M., Greenman, Yona, Stern, Naftali, Shibolet, Oren, Scapa, Erez, Yakir, Oz, Shor, Dana Ben-Ami, Bar-Yishay, Iddo, Shamai, Sivan, Sofer, Yael, Lubezky, Nir, Goykhman, Yaacov, Lahat, Guy, Wolf, Ido, Pelles, Sharon, Aizic, Asaf, Blachar, Arye, Geva, Ravit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953747/
https://www.ncbi.nlm.nih.gov/pubmed/36830943
http://dx.doi.org/10.3390/biomedicines11020407
_version_ 1784893955003908096
author Osher, Esther
Shalabna, Eiman
Klausner, Joseph M.
Greenman, Yona
Stern, Naftali
Shibolet, Oren
Scapa, Erez
Yakir, Oz
Shor, Dana Ben-Ami
Bar-Yishay, Iddo
Shamai, Sivan
Sofer, Yael
Lubezky, Nir
Goykhman, Yaacov
Lahat, Guy
Wolf, Ido
Pelles, Sharon
Aizic, Asaf
Blachar, Arye
Geva, Ravit
author_facet Osher, Esther
Shalabna, Eiman
Klausner, Joseph M.
Greenman, Yona
Stern, Naftali
Shibolet, Oren
Scapa, Erez
Yakir, Oz
Shor, Dana Ben-Ami
Bar-Yishay, Iddo
Shamai, Sivan
Sofer, Yael
Lubezky, Nir
Goykhman, Yaacov
Lahat, Guy
Wolf, Ido
Pelles, Sharon
Aizic, Asaf
Blachar, Arye
Geva, Ravit
author_sort Osher, Esther
collection PubMed
description The objective of this study was to determine the prognostic value of lymph node (LN) involvement and the LN ratio (LNR) and their effect on recurrence rates and survival in patients with pancreatic neuroendocrine tumors (PNETs) undergoing surgery. This single-center retrospective study reviewed the medical records of 95 consecutive patients diagnosed with PNETs who underwent surgery at our medical center between 1997 and 2017. The retrieved information included patient demographics, pathology reports, treatments, and oncological outcomes. Results: 95 consecutive potentially suitable patients were identified. The 78 patients with PNETs who underwent surgery and for whom there was adequate data were included in the analysis. Their mean ± standard deviation age at diagnosis was 57.4 ± 13.4 years (range 20–82), and there were 50 males (64%) and 28 females (36%). 23 patients (30%) had LN metastases (N1). The 2.5- and 5-year disease-free survival (DFS) rates for the entire cohort were 79.5% and 71.8%, respectively, and their 2- and 5-year overall survival (OS) rates were 85.9% and 82.1%, respectively. The optimal value of the LNR was 0.1603, which correlated with the outcome (2-year OS p = 0.002 HR = 13.4 and 5-year DFS p = 0.016 HR = 7.2, respectively, and 5-year OS and 5-year DFS p = 0.004 HR = 9 and p = 0.001 HR = 10.6, respectively). However, the multivariate analysis failed to show that the LNR was an independent prognostic factor in PNETs. Patients with PNETs grade and stage are known key prognostic factors influencing OS and DFS. According to our results, LNR failed to be an independent prognostic factor.
format Online
Article
Text
id pubmed-9953747
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99537472023-02-25 A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors Osher, Esther Shalabna, Eiman Klausner, Joseph M. Greenman, Yona Stern, Naftali Shibolet, Oren Scapa, Erez Yakir, Oz Shor, Dana Ben-Ami Bar-Yishay, Iddo Shamai, Sivan Sofer, Yael Lubezky, Nir Goykhman, Yaacov Lahat, Guy Wolf, Ido Pelles, Sharon Aizic, Asaf Blachar, Arye Geva, Ravit Biomedicines Article The objective of this study was to determine the prognostic value of lymph node (LN) involvement and the LN ratio (LNR) and their effect on recurrence rates and survival in patients with pancreatic neuroendocrine tumors (PNETs) undergoing surgery. This single-center retrospective study reviewed the medical records of 95 consecutive patients diagnosed with PNETs who underwent surgery at our medical center between 1997 and 2017. The retrieved information included patient demographics, pathology reports, treatments, and oncological outcomes. Results: 95 consecutive potentially suitable patients were identified. The 78 patients with PNETs who underwent surgery and for whom there was adequate data were included in the analysis. Their mean ± standard deviation age at diagnosis was 57.4 ± 13.4 years (range 20–82), and there were 50 males (64%) and 28 females (36%). 23 patients (30%) had LN metastases (N1). The 2.5- and 5-year disease-free survival (DFS) rates for the entire cohort were 79.5% and 71.8%, respectively, and their 2- and 5-year overall survival (OS) rates were 85.9% and 82.1%, respectively. The optimal value of the LNR was 0.1603, which correlated with the outcome (2-year OS p = 0.002 HR = 13.4 and 5-year DFS p = 0.016 HR = 7.2, respectively, and 5-year OS and 5-year DFS p = 0.004 HR = 9 and p = 0.001 HR = 10.6, respectively). However, the multivariate analysis failed to show that the LNR was an independent prognostic factor in PNETs. Patients with PNETs grade and stage are known key prognostic factors influencing OS and DFS. According to our results, LNR failed to be an independent prognostic factor. MDPI 2023-01-30 /pmc/articles/PMC9953747/ /pubmed/36830943 http://dx.doi.org/10.3390/biomedicines11020407 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Osher, Esther
Shalabna, Eiman
Klausner, Joseph M.
Greenman, Yona
Stern, Naftali
Shibolet, Oren
Scapa, Erez
Yakir, Oz
Shor, Dana Ben-Ami
Bar-Yishay, Iddo
Shamai, Sivan
Sofer, Yael
Lubezky, Nir
Goykhman, Yaacov
Lahat, Guy
Wolf, Ido
Pelles, Sharon
Aizic, Asaf
Blachar, Arye
Geva, Ravit
A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
title A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
title_full A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
title_fullStr A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
title_full_unstemmed A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
title_short A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
title_sort lymph node ratio model for prognosis of patients with pancreatic neuroendocrine tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953747/
https://www.ncbi.nlm.nih.gov/pubmed/36830943
http://dx.doi.org/10.3390/biomedicines11020407
work_keys_str_mv AT osheresther alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT shalabnaeiman alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT klausnerjosephm alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT greenmanyona alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT sternnaftali alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT shiboletoren alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT scapaerez alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT yakiroz alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT shordanabenami alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT baryishayiddo alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT shamaisivan alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT soferyael alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT lubezkynir alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT goykhmanyaacov alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT lahatguy alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT wolfido alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT pellessharon alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT aizicasaf alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT blachararye alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT gevaravit alymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT osheresther lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT shalabnaeiman lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT klausnerjosephm lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT greenmanyona lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT sternnaftali lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT shiboletoren lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT scapaerez lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT yakiroz lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT shordanabenami lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT baryishayiddo lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT shamaisivan lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT soferyael lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT lubezkynir lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT goykhmanyaacov lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT lahatguy lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT wolfido lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT pellessharon lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT aizicasaf lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT blachararye lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors
AT gevaravit lymphnoderatiomodelforprognosisofpatientswithpancreaticneuroendocrinetumors